Inhibrx Biosciences, Inc. (INBX) Stock Price & Analysis
Inhibrx Biosciences, Inc. (INBX) closed at USD 97.1 on Thursday, October 22, 2026, down 1.11% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 97.1; the Oct 22, 2026 session ranged USD 94.04–100.2 on volume of 249,508 shares. Market capitalization is —, with a 52-week range of USD 28.16–155.29 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:27 UTC.
Also available as compact Markdown for AI agents: nexqual.com/INBX.md
Key facts (INBX)
- 1 of 80 tracked superinvestors hold INBX (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Total return with dividends: 1Y +242.4% vs S&P 500 +14.9%; 5Y +497.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-13, EPS estimate USD -2.36, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (INBX)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | $1.8M | $200K | $1.3M | — |
| Operating income | -$219M | -$331M | -$135M | -$128M |
| Net income | -$241M | $1.69B | -$140M | -$138M |
| EPS (diluted) | -$20.48 | $112.62 | -$9.04 | — |
| Free cash flow | -$198M | -$197M | -$130M | -$132M |
| Operating margin | -12178.9% | -165724.0% | -10386.5% | — |
| Net margin | -13408.9% | 843786.0% | -10773.5% | — |
| Revenue growth | — | -88.9% | +550.0% | — |
| Cash + short-term investments | $278M | $153M | $124M | — |
| Total debt | $207M | $0K | $101M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (INBX)
P/E at fiscal year-ends: Dec 2024 0.1x.
Superinvestors (SEC 13F-HR, Q2 2026) (INBX)
1 of 80 tracked investors hold INBX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.30% | $106M | Reduced -21.8% |
Analysts (INBX)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-24 | HC Wainwright & Co. | Initiated | Buy | $245 |
Total return (dividends reinvested) (INBX)
| 1Y (from 2025-10-23) | 5Y (from 2024-05-27) | |
|---|---|---|
| Total return | +242.4% | +497.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +243.8% | +110.2% |
| Volatility (annualized) | 103.7% | 72.3% |
| Max drawdown | -44.1% (May 2026→Jul 2026) | -39.3% (May 2026→Jul 2026) |
INBX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-2.35 | $-2.39 | -1.5% | $0 | 2 |
| Next quarter (ends Dec 2026) | $-2.42 | $-2.45 | -1.4% | $0 | 2 |
| Current fiscal year (ends Dec 2026) | $-9.26 | $-9.26 | -0.1% | $0 | 2 |
| Next fiscal year (ends Dec 2027) | $-8.76 | $-6.30 | +39.0% | $36.1M | 2 |
INBX options: expected move
Options price a move of about ±20.9% (±$20.30) by Nov 20, 2026, which includes earnings on Nov 13, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 93.8% | ±20.9% |
| Dec 18, 2026 | 56 | 87.8% | ±27.3% |
| Jan 15, 2027 | 84 | 88.6% | ±33.5% |
| Feb 19, 2027 | 119 | 86.5% | ±38.6% |
| May 21, 2027 | 210 | 87.9% | ±51.5% |
30-day implied volatility 85.6% vs 54.6% realized over the last 30 trading days. Put/call ratio (volume) 0.64. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:27 UTC)
| Price | USD 97.1 |
|---|---|
| Change | ▼ 1.11% (down) |
| Previous Close | USD 97.1 |
| Open | USD 97.1 |
| Day Range | USD 94.04 – 100.2 |
| 52-Week Range | USD 28.16 – 155.29 |
| Volume | 249,508 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (INBX)
Nexqual's technical model rates INBX "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 09:27 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.64 (neutral) |
| vs SMA50 | Below (USD 103.87) |
| MACD | -2.7 (negative) |
Earnings (INBX)
| Next Earnings Date | 2026-11-13 |
|---|---|
| EPS Estimate | USD -2.36 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -2.34 vs est -2.28 ▼ miss |
| 2026-03-31 | USD -2.15 vs est -1.2 ▼ miss |
| 2025-12-31 | USD -2.11 vs est -2.08 ▼ miss |
| 2025-09-30 | USD -2.28 vs est -1.72 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financials & Fundamentals (INBX)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -1773.60% |
| Current Ratio | 5.07 |
| Total Cash | $133.34M |
| Total Debt | $181.63M |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Ownership (INBX)
| Insider Ownership | +23.08% |
|---|---|
| Institutional Ownership | +90.66% |
| Shares Outstanding | 14.72M |
| Float | 8.58M |
| Short % of Float | +31.14% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:27 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt